Inter- and Intratumor Heterogeneity of EGFR Compound Mutations in Non–Small Cell Lung Cancers: Analysis of Five Cases
- 17 September 2020
- journal article
- research article
- Published by Elsevier BV in Clinical Lung Cancer
- Vol. 22 (2), e141-e145
- https://doi.org/10.1016/j.cllc.2020.09.009
Abstract
No abstract availableKeywords
Funding Information
- Boehringer Ingelheim
- Japan Society for the Promotion of Science
This publication has 16 references indexed in Scilit:
- Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencingNature Communications, 2018
- A method of high-throughput functional evaluation of EGFR gene variants of unknown significance in cancerScience Translational Medicine, 2017
- Clinical mutational profiling of 1006 lung cancers by next generation sequencingOncotarget, 2017
- CompoundEGFRmutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinomaCancer Biology & Therapy, 2016
- Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancerLung Cancer, 2015
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6The Lancet Oncology, 2015
- Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trialsThe Lancet Oncology, 2015
- Compound EGFR Mutations and Response to EGFR Tyrosine Kinase InhibitorsJournal of Thoracic Oncology, 2013
- Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung AdenocarcinomaJournal of Clinical Oncology, 2011
- Reciprocal and Complementary Role of MET Amplification and EGFR T790M Mutation in Acquired Resistance to Kinase Inhibitors in Lung CancerClinical Cancer Research, 2010